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Life Sciences Research Unit, University of Luxembourg, L-1533, LuxembourgmiRNAs are small non-codingRNAs affecting the expression ofmany
genes and are regarded as crucial regulators involved in the ﬁne-tuning
of all cellular processes. Organ- and disease-speciﬁc miRNAs have been
described. They are not only found within cells but also in body ﬂuids,
where they are stable and can easily be detected, e.g. by RNA-Seq or
qPCR. Thus, miRNAs seem ideal biomarkers for diagnosis and prognosis
of a variety of diseases, including cancer. This applies in particular to
cell-free miRNAs from body ﬂuids because they are readily accessible
in a cost-effective way (see e.g., Schwarzenbach et al., 2014).
The study by Stark et al. (2015b), published in this issue of
EBioMedicine, describes a panel of miRNAs as potential biomarkers
in melanoma, for diagnosing early recurrence and for estimating sur-
vival. Diagnostic miRNA biomarkers might be particularly useful as a
screening tool for developing metastatic lesions and for the follow up
of stage III patients. Moreover, miRNA biomarkers with predictive
value could be supportive in the clinical management of melanoma:
e. g. patients with a low-risk score could be spared from aggressive ad-
juvant treatment and expensive imaging surveillance.
The authors startedwith the analysis of 17miRNAs, the selection cri-
terion being “high enrichment in melanoma”: most of the included
miRNAs were expressed at least 15-fold higher in a set of 55 melanoma
cell lines compared to 34 other solid cancer cell lines (Stark et al., 2015a).
When analyzing stage III and stage IV melanoma tissues, Stark and col-
leagues could identifymiRNAswhichwere predictors of tumor stage, re-
currence and overall survival. A subset of 7 miRNAs (MELmiR-7 panel)
was later derived, which was particularly informative when analyzing
the sera of melanoma patients. Within the MELmiR-7 panel, combina-
tions of 4 or 5 (serum) miRNAs were identiﬁed which allowed for
discrimination of different disease stages with high sensitivity and spec-
iﬁcity and, importantly, with a better diagnostic score than currently
applied serological tests based on LDH and S100B.
Intuitively, one might have expected that the expression of the
“melanoma-enriched” miRNAs included in the analyzed panels would
increase in tissue and serum as a function of melanoma progression. In-
triguingly, however, the expression level of the majority of the miRNAs
was lower, not higher, in the serum of melanoma patients compared to
healthy controls and was also lower in stage IV versus stage III tissueDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.011.
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rive from the tumor cells, but from other sources like blood cells or en-
dothelial cells. As discussed by the authors, the observed decreased
expression of miRNAs in the serum might also reﬂect a systemic re-
sponse to the tumor, e. g. based on a different cytokine pattern elicited
by the cancer cells and their microenvironment.
Another interesting ﬁnding was that the serum expression level
of miR-211 in stage IV patients is indicative for their survival time, a
high expression correlating with shorter survival. MiR-211 is a known
lineage-speciﬁc miRNA under MITF control, and a high serum level in
late-stage melanoma patients has been reported before (Margue et al.,
2013; Margue et al., 2015; Saldanha et al., 2013; Stark et al., 2015a).
Many of the 17 miRNAs analyzed in the present study had not been in
the focus of previous studies describing melanoma-speciﬁc miRNA sig-
natures with potential diagnostic and predictive value (e. g. Friedman
et al., 2012; Greenberg et al., 2013; Saldanha et al., 2013). We recently
analyzed a larger panel (88 serum miRNAs), selected on the basis of
whole miRNome arrays of serum samples of melanoma patients and
healthy controls (Margue et al., 2015). Also in our study, miR-211 was
among themiRNAswhich could be used to discriminate stage IV tumors
from healthy serum while miR-16 was rather down-regulated in con-
trast to the up-regulation reported by Stark. However, miR-16 levels
need to be interpreted with caution as it has been shown to be highly
expressed in erythrocytes, therefore it may be considered a marker of
hemolytic serum (Pritchard et al., 2012).
It will be important to see how well the results of the present study
involving a sensitivemethod of detection and relatively large cohorts of
patients and controls can be reproduced in other centers. As reviewed
recently by Jarry et al. (2014), non-congruence between results of dif-
ferent studies on circulating miRNAs in oncology has been a frequent
observation, due to the inherently low concentration of secreted
miRNAs, the use of different platforms andmany possible technological
pitfalls. Similar to previous initiatives regarding qPCR (MIQE) and
microarray analysis (MIAME), common guidelines regarding quality
controls of the various pre- and post-analytical steps (for extraction
methods, pre-ampliﬁcation steps, normalization factors, possible blood
cell contaminations, bioinformatic analysis, etc.) and the documentation
thereof would greatly facilitate the deﬁnition and reﬁnement of robust
miRNA biomarkers for the beneﬁt of patients with melanoma and
other cancers.
The present publication rightfully underlines that a reasoning
such as ‘miRNAs released from the tumor reﬂect miRNA expression ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is certainly too simplistic. An area of ongoing investigation is the selec-
tive sorting of intracellular miRNAs into exosomes which are then re-
leased from the cells. It seems clear that this is not a passive process;
consensus sequences within miRNAs might facilitate their secretion
(Villarroya-Beltri et al., 2013). It can be envisaged that the process of
miRNA secretion is regulated and that cancer cells might exploit this
process to secrete or retain different miRNAs to gain selective growth
advantages. Another fascinating ﬁeld of research is the investigation of
possible “messenger functions” of secreted miRNAs regarding metasta-
tic spread or drug resistance.
The study by Stark and colleagues adds novel information to the
miRNA biomarker ﬁeld in melanoma. It will now be interesting to see in
future cohorts how the MELmiR-7 panel will perform in the surveillance
of stage III patients to allow for an earlier detection of tumor recurrence,
so that adjuvant, systemic or targeted therapies can be offered at an ear-
lier time point, for the beneﬁt of the patients affected by this fatal disease.
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